Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy?
Some say that the Chinese word for "crisis" is made up of two characters, one for "danger" and the other for "opportunity." That's actually not true. However, the sentiment is often on target. While many crises do present danger, they also frequently present opportunities.
We're certainly seeing that happen with COVID-19. More than 5 million people worldwide have died from the viral disease so far. At the same time, many companies have made a lot of money during the pandemic by selling personal protective equipment, tests, therapies, and vaccines.
None of them has been a bigger financial winner than Pfizer (NYSE: PFE). The company reported $13 billion in sales of its COVID-19 vaccine Comirnaty in the third quarter alone. SVB Leerink analyst Geoffrey Porges estimates that Pfizer is set to make a stunning $131 billion in COVID-19 sales by the end of 2022. But is the pharmaceutical stock a buy?
Source Fool.com
